Dose-ranging Study of Nemolizumab in Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

July 19, 2018

Study Completion Date

September 21, 2018

Conditions
Atopic Dermatitis
Interventions
DRUG

Nemolizumab

Injection every 4 weeks during 24 weeks (last injection at week 20)

DRUG

Placebo

Injection every 4 weeks during 24 weeks (last injection at week 20)

Trial Locations (67)

10025

Galderma Investigational site, New York

10075

Galderma Investigational Site, New York

10117

Galderma Investigational Site, Berlin

10789

Galderma Investigational Site, Berlin

11375

Galderma Investigational site, Forest Hills

13385

Galderma Investigational Site, Marseille

20354

Galderma Investigational Site, Hamburg

23220

Galderma Investigational site, Richmond

27516

Galderma Investigational site, Chapel Hill

30328

Galderma Investigational site, Sandy Springs

30625

Galderma Investigational Site, Hannover

31059

Galderma Investigational Site, Toulouse

31904

Galderma Investigational site, Columbus

33075

Galderma Investigational Site, Bordeaux

33135

Galderma Investigational site, Miami

33607

Galderma Investigational site, Tampa

33624

Galderma Investigational Site, Tampa

35209

Galderma Investigational site, Birmingham

49074

Galderma Investigational Site, Osnabrück

55131

Galderma Investigational Site, Mainz

59037

Galderma Investigational Site, Lille

60561

Galderma Investigational Site, Darien

60590

Galderma Investigational Site, Frankfurt

64283

Galderma Investigational Site, Darmstadt

66215

Galderma Investigational Site, Overland Park

69120

Galderma Investigational Site, Heidelberg

70115

Galderma Investigational site, New Orleans

70718

Galderma Investigational Site, Stuttgart

72916

Galderma Investigational site, Fort Smith

75010

Galderma Investigational Site, Paris

75230

Galderma Investigational site, Dallas

76710

Galderma Investigational Site, Waco

78218

Galderma Investigational site, San Antonio

78334

Galderma Investigational Site, Farmington Hills

80337

Galderma Investigational Site, München

89129

Galderma Investigational Site, Langenau

90212

Galderma Investigational site, Beverly Hills

90274

Galderma Investigational site, Rolling Hills Estates

90404

Galderma Investigational site, Santa Monica

91054

Galderma Investigational Site, Erlangen

92701

Galderma Investigational site, Santa Ana

92708

Galderma Investigational site, Fountain Valley

94538

Galderma Investigational site, Fremont

02919

Galderma Investigational Site, Johnston

4217 QLD

Galderma Investigational Site, Benowa

NSW 2217

Galderma Investigational Site, Kogarah

VIC3002

Galderma Investigational Site, Melbourne

ACT2606

Galderma Investigational Site, Phillip

AB T3A 2N1

Galderma Investigational Site, Calgary

ON L3P 1X2

Galderma Investigational Site, Markham

ON L6J 7W5

Galderma Investigational Site, Oakville

K1G 6C6

Galderma Investigational Site, Ottawa

ON K2G 6E2

Galderma Investigational Site, Ottawa

K9J

Galderma Investigational Site, Peterborough

ON L4C

Galderma Investigational Site, Richmond Hill

QC G1V4X7

Galderma Investigational Site, Sainte-Foy

ON N2J 1C4

Galderma Investigational Site, Waterloo

06202

Galderma Investigational Site, Nice

40-123

Galderma Investigational Site, Katowice

40-648

Galderma Investigational Site, Katowice

31-024

Galderma Investigational Site, Krakow

90-436

Galderma Investigational Site, Lodz

20-080

Galderma Investigational Site, Lublin

01-817

Galderma Investigational Site, Warsaw

02-625

Galderma Investigational Site, Warsaw

02-758

Galderma Investigational Site, Warsaw

51-318

Galderma Investigational Site, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galderma R&D

INDUSTRY